Clinical trials
Unresectable Metastatic Colorectal Cancer clinical trials
Below are recruiting unresectable metastatic colorectal cancer clinical trials, each written for real people, not researchers. We’re tracking 198 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06917079RecruitingPhase 1
BBO-11818 for KRAS-mutated cancers
This trial tests a new oral drug (BBO-11818) for people with solid tumors that have a specific KRAS mutation. It's for those whose cancer has spread or cannot be removed by surgery and who have not had other cancers recently.
Los Angeles, CaliforniaAges 18 years+ - NCT06907342RecruitingPhase 2
Personalized chemo selection for advanced colorectal cancer
This trial tests whether a functional test on a tumor biopsy can help choose the best first chemotherapy regimen (FOLFOX or FOLFIRI) for people with metastatic colorectal cancer. It aims to improve outcomes by matching treatment to each person's unique tumor biology.
TrondheimAges 18 years+ - NCT06889610RecruitingPhase 2
Ablation plus drug therapy for advanced solid tumors
This trial tests combining a liver tumor ablation procedure with systemic drugs for people with advanced colorectal, breast, or melanoma cancer that has spread to the liver. The goal is to see if this approach can help when standard treatments have stopped working.
ShanghaiAges 18–80 - NCT06853496RecruitingPhase 1
RK-582 for advanced colorectal cancer
This trial tests a new type of pill called RK-582 that may help block the growth of colorectal cancer cells. It is for people whose cancer has spread and hasn't gotten better with other treatments.
Koto-ku, TokyoAges 18 years+ - NCT06856187RecruitingPhase 2
Second-line chemo plus TAS-102 combo for advanced colorectal cancer
This trial tests adding a new drug combo (TAS-102 and bevacizumab) to standard second-line treatment for advanced colorectal cancer, followed by local treatments. It may help if your first treatment stopped working and you are otherwise in good health.
Shanghai, Shanghai MunicipalityAges Any age - NCT06848842RecruitingPhase 2
Ivonescimab and chemotherapy for colorectal cancer that spread only to the liver
This trial tests a new drug called ivonescimab combined with chemotherapy for people whose colorectal cancer has spread only to the liver and cannot be surgically removed right away. The goal is to see if this combination can shrink the tumors enough to allow surgery or other treatments.
BeijingAges 18 years+ - NCT05314400Recruiting
MRI with contrast for metastatic colon cancer liver lesions
This trial studies an MRI technique using a contrast dye (gadopetate/gadolinium) to better look at liver lesions that may be colon cancer spread. It may help doctors more accurately assess which liver tumors are present and guide next steps.
London, OntarioAges 18 years+ - NCT06733038RecruitingPhase 3
Chemo plus Avastin with or without Tecentriq for advanced colorectal cancer
This trial tests whether adding the immunotherapy drug atezolizumab (Tecentriq) to standard chemotherapy (FOLFOXIRI) and bevacizumab (Avastin) is more effective as a first treatment for people with a specific type of metastatic colorectal cancer that has a high immune score and is mismatch repair proficient.
Brescia, BSAges 18–75 - NCT06696768RecruitingPhase 1
New drug plus standard chemotherapy for advanced colorectal cancer
This trial combines a new experimental drug (emavusertib) with standard chemotherapy (FOLFOX plus bevacizumab) for people with stage IV colorectal cancer who have not yet received chemotherapy. The goal is to see if the combination is safe and effective, potentially offering a new first-line treatment option.
Gainesville, FloridaAges 18 years+ - NCT06695845RecruitingPhase 2
Study of zanidatamab for HER2-positive solid tumors
This trial tests a drug called zanidatamab in people with advanced solid tumors that have high levels of HER2 protein (called HER2-positive). It aims to see if zanidatamab can shrink or slow the growth of these tumors.
Prescott, ArizonaAges 18 years+ - NCT06662786RecruitingPhase 3
Amivantamab plus chemo vs. standard chemo for left-sided colorectal cancer
This trial compares a new combination (amivantamab plus chemotherapy) with the standard treatment (cetuximab plus chemotherapy) as the first therapy for people with left-sided colorectal cancer that has spread. The goal is to see which approach works better when the tumor has no mutations in the KRAS, NRAS, or BRAF genes.
Gilbert, ArizonaAges 18 years+ - NCT06642844RecruitingPhase 3
Bevacizumab dose adjustment for colorectal cancer
This trial tests whether adjusting the dose of bevacizumab based on your blood levels can improve first-line treatment for metastatic colorectal cancer that can't be removed with surgery.
BesançonAges 18–99 - NCT06625775RecruitingPhase 1
Study of BBO-10203 for advanced solid tumors
This trial tests a new drug called BBO-10203, alone or combined with other cancer treatments, for people with certain advanced breast, colorectal, or lung cancers. It aims to see if the drug is safe and effective.
Duarte, CaliforniaAges 18 years+ - NCT06589830RecruitingPhase 2
TL938 with Trastuzumab for HER2+ Colorectal Cancer
This trial is testing a new combination of drugs (TL938 and trastuzumab) for people with a specific type of advanced colorectal cancer that is HER2-positive and RAS wild-type. It may offer a new option if you have already tried standard chemotherapy and a blood vessel-blocking drug.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06589440RecruitingPhase 2
Study of SR-8541A plus two immunotherapies for advanced colorectal cancer
This trial tests a new drug combination (SR-8541A, botensilimab, and balstilimab) for people with a specific type of metastatic colorectal cancer that is not MSI-high. It aims to see if this combination can help when other treatments have stopped working.
Morristown, New JerseyAges 18 years+ - NCT06562543RecruitingPhase 4
Fruquintinib for advanced colorectal cancer in minority populations
This trial tests a medication called fruquintinib (an oral pill) for people with advanced colorectal cancer that has not responded to prior treatments. It is specifically looking for participants who identify as Black or African American and/or Hispanic or Latino to help understand how the drug works in these groups.
Birmingham, AlabamaAges 18 years+ - NCT06562192RecruitingPhase 1
Testing a radioactive drug for advanced pancreatic, lung, breast, and colorectal cancers
This trial tests a new radioactive drug (177Lu-NNS309) for people with advanced pancreatic, lung, breast, or colorectal cancer that has not responded to prior treatments. It aims to see if the drug can target and shrink tumors.
Birmingham, AlabamaAges 18–100 - NCT06553885RecruitingPhase 2
Study of enfortumab vedotin for advanced colorectal or liver cancer
This trial tests a drug called enfortumab vedotin for people whose colorectal or liver cancer has spread or cannot be removed and has stopped responding to or is intolerant to standard treatments. The drug is given through a vein and works by targeting cancer cells.
Tampa, FloridaAges 18 years+ - NCT05107674RecruitingPhase 1
Early drug study for advanced cancers that have limited options
This Phase 1 study tests NX-1607 in adults with advanced cancers that are hard to treat with standard care. It focuses on safety and early signs of how well the drug may work in specific cancer types.
Duarte, CaliforniaAges 18 years+ - NCT06440005RecruitingPhase 1
Testing AGX101 for advanced solid tumors
This study tests a new drug called AGX101 for people with advanced solid tumors that have not responded to other treatments. The goal is to see if it is safe and if it can shrink tumors or slow their growth.
Los Angeles, CaliforniaAges 18 years+ - NCT06412198RecruitingPhase 1/Phase 2
Combination Drug Study for KRAS G12C Colorectal Cancer
This trial tests three drugs (adagrasib, cetuximab, cemiplimab) together for colorectal cancer with a KRAS G12C mutation. The goal is to see if this combination shrinks tumors or slows cancer growth.
Boston, MassachusettsAges 18 years+ - NCT06411691RecruitingPhase 1
Vaccine plus immunotherapy for KRAS-mutant cancers
This trial tests a cancer vaccine designed to target KRAS-mutated tumors, combined with two immunotherapy drugs, for people with advanced colorectal or pancreatic cancer. It may help the immune system recognize and attack cancer cells.
Baltimore, MarylandAges 18 years+ - NCT06395519RecruitingPhase 1/Phase 2
Study of ETX-19477 for advanced solid tumors
This trial tests an experimental drug called ETX-19477 for people with advanced solid tumors that have stopped responding to other treatments. It aims to see if the drug is safe and effective, especially for those with certain genetic changes (BRCA2 mutations).
Phoenix, ArizonaAges 18 years+ - NCT06369259RecruitingPhase 2
Combination treatment for advanced colorectal cancer that resisted standard therapy
This clinical trial tests a new combination of three drugs for people with advanced colorectal cancer that has not responded to standard anti-EGFR treatments. The goal is to see if this combination can shrink tumors or slow the cancer down.
Houston, TexasAges 18 years+
Hear when a new Unresectable Metastatic Colorectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for unresectable metastatic colorectal cancer?
- Yes. Clin2 currently lists 198 recruiting unresectable metastatic colorectal cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a unresectable metastatic colorectal cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a unresectable metastatic colorectal cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.